Extracellular vesicles, which are nano-sized particles released by cells, play a pivotal role in cell-to-cell communication. They serve as carriers of various biomolecules, including proteins, lipids, and RNA, facilitating physiological processes. Importantly, their presence in bodily fluids and their interaction with recipient cells make them fascinating subjects of investigation for understanding disease mechanisms, particularly in atherosclerosis.

The authors, led by researchers Zhang, W., and Wu, meticulously explored diverse sources of EVs in the context of atherosclerosis. Their findings indicate that these vesicles can originate from various cell types, including endothelial cells, smooth muscle cells, and macrophages. This diversity not only highlights the complexity of atherosclerotic pathology but also underscores the potential for utilizing EVs as biomarkers for disease progression.

Moreover, the research provides compelling evidence that the cargo within EVs can vary significantly depending on their originating cell type. For instance, EVs derived from macrophages exhibit pro-inflammatory components, while those from endothelial cells may carry regenerative signals. This differential cargo composition suggests that targeting specific EV populations might offer tailored therapeutic strategies, enhancing efficacy and minimizing adverse effects in patients.

In addition to their biomarker potential, the study elaborates on the therapeutic applications of EVs. The authors describe how engineering EVs to deliver therapeutic agents, such as anti-inflammatory drugs or gene-editing components, could pave the way for innovative treatments. This notion of harnessing the natural transport capabilities of EVs aligns with current trends in precision medicine, where treatments are increasingly individualized based on a patient’s unique profile.

The implications of these findings reach beyond atherosclerosis. The study’s insights into the diverse roles of EVs could extend to other cardiovascular diseases and conditions characterized by inflammation. By advancing our understanding of EV-mediated pathways, researchers may unveil commonalities that transcend individual disease states, leading to broader therapeutic avenues.

Furthermore, the research emphasizes the importance of understanding the environmental factors that influence EV biogenesis. Conditions such as hypoxia or oxidative stress, prevalent in atherosclerotic plaques, significantly impact the production and functionality of EVs. Therefore, elucidating the relationship between these environmental cues and EV characteristics will be essential for developing a comprehensive therapeutic strategy.

As the field of EV research continues to grow, the necessity for standardized methods to isolate and characterize these vesicles becomes paramount. The study highlights that variability in isolation protocols could lead to discrepancies in study outcomes, necessitating collaborative efforts to establish robust methodologies. Such standardization could also facilitate the translation of findings from bench to bedside, ensuring that therapeutic applications of EVs reach clinical settings efficiently.

To further explore the potential of EVs in atherosclerosis, longitudinal studies will be crucial to track the changes in EV profiles during disease progression and treatment responses. By understanding how EVs evolve in relation to therapeutic interventions, researchers can better assess their utility as dynamic biomarkers for monitoring disease activity and treatment efficacy.

The research conducted by Zhang et al. serves as a clarion call for the scientific community to invest in understanding the multifaceted roles of EVs. Not only do these vesicles represent a promising frontier for enhancing diagnosis and treatment, but they also challenge existing paradigms in our approach to cardiovascular diseases.

Moreover, the implications of this research extend into the realms of regulatory science and therapeutic approval processes. As EV-based therapies move closer to realization, regulatory agencies will need to address the unique challenges associated with these nanoscale entities. Establishing clear guidelines for the manufacturing, testing, and approval of EV products will be essential to ensure their safety and efficacy in clinical applications.

As we stand on the cusp of potential breakthroughs in atherosclerosis treatment, the insights gained from this research underscore the need for an integrated approach that encompasses basic science, clinical research, and regulatory frameworks. Effective collaboration among researchers, clinicians, and regulatory bodies will be essential to translate findings into real-world therapies that can significantly impact patient outcomes.

In conclusion, the exploration of extracellular vesicles in atherosclerosis opens a myriad of possibilities that bridge scientific understanding and therapeutic innovation. As the complexities of these vesicles become clearer, they may well form the foundation for next-generation therapies that not only combat atherosclerosis but also enhance our understanding of cardiovascular health.

Subject of Research: Extracellular Vesicles in Atherosclerosis

Article Title: Diversity of extracellular vesicle sources in atherosclerosis: role and therapeutic application

Article References:

Zhang, Y., Zhang, W., Wu, Z. et al. Diversity of extracellular vesicle sources in atherosclerosis: role and therapeutic application.
Angiogenesis 28, 34 (2025). https://doi.org/10.1007/s10456-025-09983-7

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s10456-025-09983-7

Keywords: Extracellular vesicles, atherosclerosis, cardiovascular disease, biomarkers, therapeutic applications.

Atherosclerosis, the pathological underpinning of many heart attacks and strokes, involves complex cellular interactions and gene regulatory networks modulated by miRNAs. Therapeutic approaches now leverage the nuanced roles miRNAs play in endothelial cells, macrophages, and vascular smooth muscle cells to stabilize plaques, reduce inflammation, and prevent vascular occlusion. These interventions transcend traditional pharmacology by deploying synthetic delivery systems, including nanoparticles and engineered exosomes, designed to modulate miRNA expression with high precision.

Salvianolic acid, a biologically active component derived from Salvia miltiorrhiza, exemplifies such targeted chemical therapies. It operates by upregulating let-7g expression in macrophages, leading to decreased foam cell formation—a critical step in plaque development—while simultaneously downregulating miR-338-3p in endothelial cells to protect against apoptosis. Moreover, this compound induces the transfer of miR-204-5p via endothelial cell-derived extracellular vesicles to smooth muscle cells, activating autophagy pathways that suppress cell death and foster plaque stability. Such multi-cellular regulatory effects underscore the therapeutic finesse miRNA modulation can achieve.

Parallel to chemical agents, nanotechnology innovations have revolutionized miRNA delivery and targeting. Surface modification of extracellular vesicles or nanostructures with ligands like hyaluronic acid enables selective binding to CD44 receptors on pro-inflammatory macrophages in atheromas, facilitating the enhanced delivery of miR-34c-5p and consequent reprogramming of macrophages from the pro-inflammatory M1 to the reparative M2 phenotype. This repolarization reduces local inflammation and supports vascular healing. Likewise, ultrasound-targeted microbubble disruption facilitates the selective delivery of miR-145a-5p to vascular smooth muscle cells, promoting a contractile phenotype essential for vascular integrity.

Another remarkable vector involves spherical nucleic acid nanostructures carrying miR-146a, which can autonomously enter macrophages and endothelial cells to regulate NF-κB signaling, a pivotal inflammatory cascade in atherosclerosis progression. Intriguingly, nanoparticles with the pH low insertion peptide (pHLIP) have been engineered to transport antisense oligonucleotides against miR-33 selectively into macrophages, thereby enhancing the expression of fibrogenic genes essential for plaque stabilization in advanced disease stages.

When atherosclerosis culminates in myocardial infarction, therapeutic miRNA modulation extends its utility in repairing ischemia-induced cardiac damage. Exosomes harvested from diverse cell sources such as MSCs, macrophages, and adipose tissue have emerged as dynamic delivery vehicles, transferring cardioprotective miRNAs to damaged heart tissues. For instance, miR-132-3p-enriched exosomes from M2 macrophages accelerate post-infarction angiogenesis by targeting thrombospondin-1, a known angiogenesis inhibitor, thereby fostering vascular repair.

Further refinements include the pretreatment of MSC-derived exosomes with vericiguat, which augments the expression of miR-1180-3p targeting ETS1, consequently inhibiting fibroblast proliferation and curbing maladaptive cardiac fibrosis. Precision delivery mechanisms such as ultrasound-targeted microbubble disruption of miR-125b combined with MSC membrane ligands have demonstrated efficacy in reducing cardiomyocyte death and fibroblast growth, highlighting the intersection of bioengineering and gene regulation.

Genome editing technologies have also converged with exosome biology to enable cardiac-specific modulation of detrimental miRNAs. Loading single-guide RNA ribonucleoprotein complexes against miR-34a into cardiac-targeted EVs attenuates cardiomyocyte apoptosis, offering a powerful gene-editing paradigm for myocardial injury. Additionally, exosomal delivery of miRNA combinations like miR-148a-3p can reprogram cardiac fibroblasts into functional muscle cells, offering prospects not merely to limit damage but to regenerate myocardial tissue.

Cerebral infarction, often complicated by the impermeability of the blood-brain barrier, presents additional therapeutic challenges. Nevertheless, engineered extracellular vesicles embedded with superparamagnetic iron oxide nanoparticles display remarkable capability in traversing this barrier and restoring neuronal mitochondrial function through modulation of the miR-1228-5p/TRAF6/NOX1 axis. Similarly, miR-21-5p from adipose tissue-derived stem cell exosomes induces microglial polarization toward the anti-inflammatory M2 phenotype via the PIK3R1/PI3K/AKT pathway, mitigating post-stroke neuroinflammation.

Hypoxia-conditioned MSC exosomes enriched with miR-214-3p promote cerebral angiogenesis through the PTEN/Akt signaling pathway, highlighting the adaptability of stem cell derivatives in ischemic brain repair. Innovative probes exploiting aggregation-induced emission properties have been developed to label endothelial cell-derived EVs, which ferry miR-155-5p into astrocytes and stimulate neurological recovery by downregulating the pro-inflammatory c-Fos/AP-1 signaling axis.

Neuromodulatory strategies also include pre-treating astrocytes with berberine to induce extracellular vesicle release containing miR-182-5p, which targets Rac1 to suppress neuroinflammation, thereby improving brain injury outcomes. Nanodelivery platforms like the Ca-MOF system facilitate efficient miR-124 transport, promoting neural stem cell differentiation into mature neurons vital for functional restoration post-infarction.

Circular RNA (circRNA)-modified adipose-derived stem cell exosomes offer another layer of regulation by downregulating miR-124-3p in the hippocampus and upregulating SIRT7, effectively alleviating neuronal injury and converting microglia to an anti-inflammatory state. Such multilayered regulatory circuits reveal how epigenetic and post-transcriptional modifications can be harnessed synergistically for neuroprotection.

Complementing these biological strategies, certain chemical agents and physical therapies like electroacupuncture have demonstrated neuroprotective efficacy via miRNA modulation. Electroacupuncture upregulates miR-142-5p, suppressing ADAMTS1, and consequently activating the VEGF/PI3K/AKT/eNOS pathway, which reduces infarct size. Simultaneously, it modulates miR-7 expression to derepress KLF4/VEGF and angiopoietin-2, enhancing post-stroke angiogenesis. Acupuncture also elevates miR-34c-5p to enhance cellular autophagy, a critical survival pathway during ischemic stress.

Interventions at the extracellular vesicle level extend to lithium-pretreated MSCs, whose EVs carrying miR-1906 inhibit the NF-κB pathway by targeting TLR4, lowering inflammatory responses. Transcranial focused ultrasound stimulation has been shown to elevate Nespas expression, reducing miR-383-3p and permitting expression of SHP2, a regulator that mitigates microglial pro-inflammatory cytokine production, revealing non-pharmacological approaches to influence miRNA networks.

The translational promise of miRNA therapeutics lies in their dual capacity to target upstream pro-thrombotic and inflammatory mechanisms in both myocardial and cerebral infarctions, addressing the root causes of ischemic events. By developing antagonists or mimics against key miRNAs involved in thrombosis and vascular dysfunction, it is conceivable to achieve simultaneous protection against both heart attacks and strokes.

However, post-infarction phases demand broad-spectrum neuroprotective and cardioprotective miRNA strategies that attenuate reperfusion injury, modulate oxidative stress, and promote tissue remodeling. The dissimilar microenvironment, cellular architecture, and presence of the blood-brain barrier necessitate specialized delivery systems and targeted validation in each organ to avert off-target effects.

Notably, cerebral infarction therapies confront additional pharmacokinetic challenges due to the blood-brain barrier’s selective permeability. Innovative nanocarriers, engineered EVs, and peptide-modified delivery platforms are crucial to overcoming this hurdle, ensuring therapeutic miRNAs reach neuronal targets efficiently.

As research progresses, the convergence of molecular biology, nanotechnology, and bioengineering is poised to revolutionize treatment paradigms for cardiovascular and cerebrovascular diseases. Therapeutics that harness the intricate regulatory roles of miRNAs promise a future where heart and brain infarctions are not only better managed but potentially reversed at the molecular level.

This burgeoning field holds the key to unlocking precision medicine solutions that address the multifaceted nature of ischemic diseases, coupling targeted gene regulation with advanced delivery technologies. In doing so, miRNA-based therapies stand to transform the landscape of chronic vascular diseases and their acute catastrophic sequelae.

Subject of Research: Harnessing microRNA therapeutics in the treatment of heart and brain infarctions related to atherosclerosis.

Article Title: Harnessing miRNA therapeutics: a novel approach to combat heart and brain infarctions in atherosclerosis.

Article References:
Wang, J., Li, Y., Wang, H. et al. Harnessing miRNA therapeutics: a novel approach to combat heart and brain infarctions in atherosclerosis. Cell Death Discov. 11, 482 (2025). https://doi.org/10.1038/s41420-025-02649-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02649-9

Atherosclerotic plaques develop over decades, characterized by the accumulation of lipids, immune cells, and fibrous material inside arterial walls. These plaques can rupture or erode, precipitating acute cardiovascular events that kill millions globally each year. Traditional bulk tissue analyses have obscured the cellular heterogeneity and subtle phenotypic shifts that dictate plaque stability or vulnerability. The advent of single-cell RNA sequencing allows scientists to dissect tissues at unprecedented resolution, cataloging every cell type and state. The team behind this latest atlas applied these methods systematically to human atherosclerotic plaques, generating a detailed cellular map that captures both expected and novel cell populations.

Employing samples from patients undergoing carotid endarterectomy, the researchers performed single-cell transcriptomic profiling on thousands of cells isolated directly from plaques. Their analysis revealed an astonishing diversity of immune and stromal cells, including multiple macrophage subsets, smooth muscle cell phenotypes, endothelial subpopulations, and immune lymphocytes. The identification of distinct macrophage states, some pro-inflammatory and others associated with tissue remodeling or lipid handling, underscores the complex immunobiology of plaques. Distinct smooth muscle cell subsets were also found that differentially contribute to matrix deposition or inflammatory processes, highlighting their dual and sometimes paradoxical roles in plaque progression.

Beyond cataloging cell types, the study integrates spatial transcriptomics to link molecular profiles with anatomic localization within plaques. This spatial mapping revealed that certain inflammatory macrophages cluster near regions of lipid cores, while fibrous cap areas are enriched for contractile smooth muscle cells. Such insights shed light on the microenvironmental niches that regulate plaque stability. The multilayered approach combining single-cell and spatial data sets a new standard for tissue atlases, providing a template for dissecting any complex pathology with cellular precision.

The data uncovered previously unrecognized cellular cross-talk mechanisms driving plaque evolution. For example, interactions between macrophage subsets and endothelial cells via specific chemokines suggest feedback loops that amplify local inflammation or promote vascular remodeling. Moreover, the atlas highlights transcriptional programs responsive to oxidative stress and hypoxia within plaques, conditions known to exacerbate tissue damage. These findings open new investigative frontiers into how microenvironmental stressors reshape cellular phenotypes and contribute to plaque destabilization.

Importantly, this single-cell atlas is not just a descriptive resource but a powerful platform for identifying therapeutic targets. By pinpointing specific cell subsets and their signaling pathways that correlate with high-risk plaques, the research provides candidate molecules for drug development. Interventions aimed at modulating macrophage phenotype transitions or enhancing the stability-promoting smooth muscle cell populations could revolutionize treatment strategies. Current cardiovascular therapies largely focus on systemic lipid lowering; targeted modulation at the plaque microenvironment level offers a complementary approach with potentially greater efficacy.

The study’s implications extend beyond atherosclerosis, demonstrating the transformative potential of integrated multiomic and spatial profiling technologies in vascular biology. This atlas serves as a proof-of-concept for applying single-cell approaches to other complex tissues where cellular heterogeneity underlies disease outcomes. Moreover, as cardiovascular diseases frequently intersect with metabolic and inflammatory disorders, understanding cell signaling networks in plaques may provide insight relevant to systemic health.

The research team also constructed a publicly accessible interactive database allowing scientists worldwide to explore and mine the single-cell profiles. This democratization of data accelerates discovery by fostering cross-disciplinary collaborations. Computational biologists, immunologists, and clinicians can interrogate the atlas to generate hypotheses, correlate findings with clinical parameters, and design experiments to validate targets. The open-access nature exemplifies modern science’s shift towards transparency and reproducibility.

From a methodological standpoint, the study exemplifies the meticulous optimization of tissue processing, cell dissociation, and sequencing protocols required for producing high-quality single-cell data from challenging human samples. Preserving cell viability and transcript integrity in fibrotic and lipid-laden plaques is non-trivial, but essential for robust insights. The investigators detail their workflow, paving the way for replication and adaptation by others studying hard-to-access tissues.

The integration of computational analytical pipelines was equally crucial, with advanced clustering algorithms and differential expression analyses resolving subtle phenotypic distinctions that evade conventional approaches. Machine learning methods identified rare and transitional cell states that may represent key nodes in plaque progression. Furthermore, trajectory inference analyses mapped developmental-like paths among smooth muscle and immune cells, revealing dynamic phenotype plasticity within lesions.

In summary, this pioneering work transforms our conceptual framework of atherosclerosis, moving from a simplified endothelial-immune lipid model toward a multidimensional cellular ecosystem paradigm. Recognizing plaques as complex organs composed of interacting cell communities reshapes research and clinical landscapes. Future studies building upon this atlas hold promise for precise diagnostics and personalized therapeutics that can preempt catastrophic cardiovascular events.

As cardiovascular disease continues to exact a devastating global toll, innovative approaches like this integrated single-cell atlas bring hope for early detection, risk stratification, and effective intervention. By decoding the cellular language of plaques, scientists are moving closer to demystifying—and ultimately defeating—one of humanity’s deadliest foes. This study stands as a testament to the power of interdisciplinary research and cutting-edge technology to illuminate complex biology and translate insights into lifesaving medical advances.

Subject of Research: Integrated single-cell analysis of human atherosclerotic plaques revealing cellular heterogeneity and interactions within lesions.

Article Title: Integrated single-cell atlas of human atherosclerotic plaques

Article References:
Traeuble, K., Munz, M., Pauli, J. et al. Integrated single-cell atlas of human atherosclerotic plaques. Nat Commun 16, 8255 (2025). https://doi.org/10.1038/s41467-025-63202-x

Image Credits: AI Generated